Use Biovail Corporation media headlines together with your portfolio to hedge against foreign markets instabilities and to determine Fund optimization strategy that fits your criteria.
Valeant Pharmaceuticals International, Inc. (VRX) recently announced that it has entered into an agreement to acquire Russian specialty pharmaceutical company, Natur Produkt International, JSC.
Valeant Pharmaceuticals to Expend Presence in Russia; Acquires Natur Produkt ... - Galaxy Stocks
Proactive Investors USA & Canada - Mar 27, 2012
Toronto's main market was down Tuesday afternoon as commodity prices fell and US consumer confidence for March dipped. As of around 12:25pm ET, the main S&P/TSX Composite Index was down 30.81 points, or 0.25%, while the more junior S&P/TSX Venture ...
4-traders - Mar 27, 2012
Bausch + Lomb Monday agreed to acquire ISTA Pharmaceuticals Inc. (>> ISTA Pharmaceuticals, Inc.), swooping in with a higher offer for the eye-care company deal less than two months after a rival suitor withdrew its bid.
BusinessWeek - Mar 26, 2012
By Ryan Flinn on March 27, 2012 Ista climbed to $9.03 at 9:45 am New York time. Bausch (BOL) will pay $9.10 a share in cash for the Irvine, California-based company, 8.6 percent more than the closing price yesterday.
Bloomberg - Mar 26, 2012
Ista Pharmaceuticals Inc. (ISTA), the maker of eye medications, rose 7.8 percent after agreeing to be bought by Bausch & Lomb Inc. (BOL) for $500 million.
Valeant target Ista snapped up by Bausch & Lomb for $500 mln - Proactive Investors USA & Canada
Bausch & Lomb to acquire ISTA in cash deal - MarketWatch
NEW YORK (AVAFIN) -- Shares of VRX settled the day down $0.25 to $47.98 on lighter than average volume. On Thursday the stock price crossed below the 50-day moving average indicating a likely bearish trend.
Canadian pharmaceuticals company Valeant Pharmaceuticals International, Inc. (VRX) recently announced that it has entered into a definitive agreement to acquire private eye care company, Eyetech, Inc., signaling management's increasing interest to ...
By Valeant Pharmaceuticals International, Inc. BRIDGEWATER, NJ, Feb. 15, 2012 -- /PRNewswire/ -- The FDA has approved the addition of a secondary supplier of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe ...
Additional Manufacturer of Methoxsalen Approved by FDA (VRX) - StreetInsider.com (subscription)
By OptionMonster 02/14/12 - 05:06 AM EST By David Russell, reporter at OptionMonster NEW YORK (OptionMonster) -- Valeant Pharmaceuticals (VRX) has been an absolute monster stock for several months, and option traders are betting that the run will ...
Option Bulls Bet Valeant's Monster Run Will Continue - CNBC.com
MISSISSAUGA, Ontario, Feb. 13, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced the successful syndication of a $600 million senior secured Tranche B Term Loan facility under its existing senior secured ...
FierceBiotech - Feb 13, 2012
Valeant Pharmaceuticals today continued its restless buyout spree, snapping up Eyetech, a small FL-based company that sells the anti-VEGF pioneer Macugen in the US And while Valeant ($VRX) didn't spell out the numbers, it carefully noted that it was ...
NASDAQ - Feb 13, 2012
(RTTNews.com) - Specialty pharmaceutical company Valeant Pharmaceutical International Inc (VRX, VRX.TO) Monday announced that it has agreed to acquire Eyetech Inc., a privately-owned ophthalmic biotechnology company dedicated to the treatment of ...
MISSISSAUGA, Ontario, Feb. 13, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has agreed to acquire Eyetech Inc., a privately-owned ophthalmic biotechnology company dedicated to ...
Investorplace.com - Feb 8, 2012
Restating the opportunities investors have in making money from the health care sector is so redundant it boarders on insanity. With that said, it would be insane for you not to see the benefit investing in this sector will have on your portfolio.
Proactive Investors USA & Canada - Feb 1, 2012
Canadian drug company Valeant Pharmaceuticals (TSE:VRX) Wednesday purchased Brazil's Probiotica Laboratorios for 150 million Brazilian real - $85.69 million - to boost its presence in the sports food supplement market.
Valeant buys Brazilian sports nutrition, food supplement company for $86M - CanadianBusiness.com
Based on recorded statements Biovail Corporation has Minimum Initial Investment of 0.0. This indicator is about the same for null average (which is currently at 0.0) family, and about the same as minimumInitialInvestment (which currently averages 0.0) category, This indicator is about the same for all funds average (which is currently at 0.0).
Fund managers put minimum investment restrictions on fund investments in order to allow the fund to function properly. Minimum restrictions allow fund managers to regulate cash flows of the fund, while guarding it from random trades that may negatively affect fund strategy.
Biovail Corporation has Year to Date Return of 0.0%. This indicator is about the same for null average (which is currently at 0.0) family, and about the same as yearToDateReturn (which currently averages 0.0) category, This indicator is about the same for all funds average (which is currently at 0.0).
Year-To-Date typically refers to a period starting from the beginning of the current year, and continuing up to the present day. Investors should becareful when comparing YTD ratios if not much of the year has occurred as research shows that YTD measures are more sensitive to early periods than late.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Management
Discussion
